A phase 2, multicenter study to evaluate the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-145) for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC).

Rom S. Leidner,Ammar Sukari,Christine H. Chung,James Ohr,Missak Haigentz,Ezra E.W. Cohen,Robert James Brown,Samuel Suzuki,Igor Gorbatchevsky,Maria Fardis,Robert L. Ferris

A phase 2, multicenter study to evaluate the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-145) for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC).

2018

Rom S. Leidner
Ammar Sukari
Christine H. Chung
James Ohr
Missak Haigentz
Ezra E.W. Cohen
Robert James Brown
Samuel Suzuki
Igor Gorbatchevsky
Maria Fardis
Robert L. Ferris

TPS6096Background: Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) has demonstrated efficacy in the treatment of immunogenic tumors with high mutation loads, such as melanoma....

Keywords:

Carcinoma
Cancer research
Pathology
Medicine
Tumor-infiltrating lymphocytes
Melanoma
autologous tumor
head and neck
Oncology
Cell therapy
Internal medicine
multicenter study
basal cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations